The Oxford Uehiro Centre for Practical Ethics, University of Oxford, Oxford, UK.
Oxford Functional Neurosurgery, University of Oxford, Oxford, UK.
Neuromodulation. 2018 Feb;21(2):135-143. doi: 10.1111/ner.12613. Epub 2017 May 30.
Innovative neurosurgical treatments present a number of known risks, the natures and probabilities of which can be adequately communicated to patients via the standard procedures governing obtaining informed consent. However, due to their novelty, these treatments also come with unknown risks, which require an augmented approach to obtaining informed consent.
This paper aims to discuss and provide concrete procedural guidance on the ethical issues raised by serious unexpected complications of novel deep brain stimulation treatments.
We illustrate our analysis using a case study of the unexpected development of recurrent stereotyped events in patients following the use of deep brain stimulation (DBS) to treat severe chronic pain. Examining these unexpected complications in light of medical ethical principles, we argue that serious complications of novel DBS treatments do not necessarily make it unethical to offer the intervention to eligible patients. However, the difficulty the clinician faces in determining whether the intervention is in the patient's best interests generates reasons to take extra steps to promote the autonomous decision making of these patients.
We conclude with clinical recommendations, including details of an augmented consent process for novel DBS treatment.
创新性神经外科治疗存在许多已知风险,这些风险的性质和概率可以通过规范知情同意书获取的标准程序向患者充分说明。然而,由于其新颖性,这些治疗方法也存在未知风险,这需要采用增强的方法来获得知情同意。
本文旨在讨论并提供关于新型深部脑刺激治疗严重意外并发症所引发的伦理问题的具体程序指导。
我们使用深部脑刺激(DBS)治疗严重慢性疼痛患者中出现复发性刻板事件的意外发展的案例研究来说明我们的分析。我们根据医疗伦理原则来研究这些意外并发症,认为新型 DBS 治疗的严重并发症不一定使向符合条件的患者提供干预措施不道德。然而,临床医生在确定干预措施是否符合患者最佳利益方面所面临的困难,为促进这些患者的自主决策提供了额外的理由。
我们的结论是,包括新型 DBS 治疗增强同意程序的细节在内的临床建议。